These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 34178702)

  • 1. Retraction: Peg-Asparaginase-Associated Pancreatitis in Chemotherapy-Treated Pediatric Patients: A 5-Year Retrospective Study.
    Frontiers Editorial Office
    Front Oncol; 2021; 11():709636. PubMed ID: 34178702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Peg-Asparaginase-Associated Pancreatitis in Chemotherapy-Treated Pediatric Patients: A 5-Year Retrospective Study.
    Zhang YY; Yang QS; Qing X; Li BR; Qian J; Wang Y; Ning BT
    Front Oncol; 2020; 10():538779. PubMed ID: 33194600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
    Christ TN; Stock W; Knoebel RW
    J Oncol Pharm Pract; 2018 Jun; 24(4):299-308. PubMed ID: 28355969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful use of octreotide as a chemoprotectant for prevention of PEG-asparaginase-induced pancreatitis.
    Buie LW; Moore J; van Deventer H
    Pharmacotherapy; 2014 Aug; 34(8):e149-51. PubMed ID: 25112526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting asparaginase-associated pancreatitis.
    Knoderer HM; Robarge J; Flockhart DA
    Pediatr Blood Cancer; 2007 Oct; 49(5):634-9. PubMed ID: 16937362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent Versus Continuous PEG-Asparaginase to Reduce Asparaginase-Associated Toxicities: A NOPHO ALL2008 Randomized Study.
    Albertsen BK; Grell K; Abrahamsson J; Lund B; Vettenranta K; Jónsson ÓG; Frandsen TL; Wolthers BO; Heyman M; Schmiegelow K
    J Clin Oncol; 2019 Jul; 37(19):1638-1646. PubMed ID: 30978155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asparaginase-associated pancreatitis in children with acute lymphoblastic leukaemia in the NOPHO ALL2008 protocol.
    Raja RA; Schmiegelow K; Albertsen BK; Prunsild K; Zeller B; Vaitkeviciene G; Abrahamsson J; Heyman M; Taskinen M; Harila-Saari A; Kanerva J; Frandsen TL;
    Br J Haematol; 2014 Apr; 165(1):126-33. PubMed ID: 24428625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of L-asp Activity, Anti-L-asp Antibody, Asn and Gln With Adverse Events Especially Anaphylaxis Risks in PEG-asp-Contained Regime Treated Pediatric ALL Patients.
    Wu J; Chen C; Huang S; Shen S; Chen J; Zhang S
    Technol Cancer Res Treat; 2020; 19():1533033820980113. PubMed ID: 33287663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-asparaginase-induced severe necrotizing pancreatitis successfully treated with percutaneous drainage.
    Top PC; Tissing WJ; Kuiper JW; Pieters R; van Eijck CH
    Pediatr Blood Cancer; 2005 Jan; 44(1):95-7. PubMed ID: 15368548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retraction: Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCϵ/PKCϵ Signaling Pathway.
    Frontiers Editorial Office
    Front Oncol; 2021; 11():707608. PubMed ID: 34136414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional Study.
    Silva WFD; Massaut IHB; Bendlin RM; Rosa LI; Velloso EDRP; Rego EM; Rocha V
    Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):e523-e528. PubMed ID: 32389674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retraction: The value, diagnostic efficacy and clinical significance of functional magnetic resonance imaging in evaluating the efficacy of neoadjuvant chemotherapy in patients with triple negative breast cancer.
    Frontiers Editorial Office
    Front Oncol; 2024; 14():1383383. PubMed ID: 38450197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia.
    Ettinger LJ; Kurtzberg J; Voûte PA; Jürgens H; Halpern SL
    Cancer; 1995 Mar; 75(5):1176-81. PubMed ID: 7850718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retraction: Effects of Aidi injection on life quality and incidence of adverse reactions in patients with non-small cell lung cancer compared with traditional chemotherapy: a systematic review and meta-analysis.
    Frontiers Editorial Office
    Front Oncol; 2024; 14():1383346. PubMed ID: 38440226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged first-line PEG-asparaginase treatment in pediatric acute lymphoblastic leukemia in the NOPHO ALL2008 protocol-Pharmacokinetics and antibody formation.
    Tram Henriksen L; Gottschalk Højfeldt S; Schmiegelow K; Frandsen TL; Skov Wehner P; Schrøder H; Klug Albertsen B;
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28660740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retraction: The efficacy and adverse effects of anlotinib in the treatment of high-grade glioma: a retrospective analysis.
    Frontiers Editorial Office
    Front Oncol; 2024; 14():1383410. PubMed ID: 38444679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
    Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
    Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retraction: RBFOX3 Promotes Gastric Cancer Growth and Progression by Activating HTERT Signaling.
    Frontiers Editorial Office
    Front Oncol; 2021; 11():738970. PubMed ID: 34532292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile of a single pegylated asparaginase (PEG-ASP) dose in remission induction for acute lymphoblastic leukemia (ALL).
    Helbig G; Armatys A; Boral K; Kopinska AJ; Wozniczka K; Dworaczek M; Chromik K; Koclega A; Panz-Klapuch M; Wysocka M; Janikowska A
    Neoplasma; 2018 Nov; 65(6):993-997. PubMed ID: 29940768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, efficacy, and clinical utility of asparaginase in the treatment of adult patients with acute lymphoblastic leukemia.
    Koprivnikar J; McCloskey J; Faderl S
    Onco Targets Ther; 2017; 10():1413-1422. PubMed ID: 28331334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.